Literature DB >> 25870067

Antimalarial activity of tulathromycin in a murine model of malaria.

Nicolas Villarino1, Joshua E Denny2, Nathan W Schmidt3.   

Abstract

There is an urgent need for new antimalarial agents and strategies to treat and control malaria. This study shows an antiplasmodium effect of tulathromycin in mice infected with Plasmodium yoelii. The administration of tulathromycin around the time of infection prevented the progression of disease in 100% of the animals. In addition, highly parasitized mice treated with tulathromycin showed a decreased parasite burden and cleared the parasite faster than did untreated infected mice.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25870067      PMCID： PMC4432142          DOI： 10.1128/AAC.02858-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle.

Authors:  Marcus A Nowakowski; Philip B Inskeep; Jim E Risk; Terry L Skogerboe; Hafid A Benchaoui; Todd R Meinert; John Sherington; Simon J Sunderland
Journal:  Vet Ther       Date:  2004

2.  Analysis of serial measurements in medical research.

Authors:  J N Matthews; D G Altman; M J Campbell; P Royston
Journal:  BMJ       Date:  1990-01-27

3.  Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys.

Authors:  S K Puri; N Singh
Journal:  Exp Parasitol       Date:  2000-01       Impact factor: 2.011

Review 4.  The public health impact of chloroquine resistance in Africa.

Authors:  J F Trape
Journal:  Am J Trop Med Hyg       Date:  2001 Jan-Feb       Impact factor: 2.345

5.  Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.

Authors:  J A Harris; A Kolokathis; M Campbell; G H Cassell; M R Hammerschlag
Journal:  Pediatr Infect Dis J       Date:  1998-10       Impact factor: 2.129

Review 6.  Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update.

Authors:  Olli Ruuskanen
Journal:  Pediatr Infect Dis J       Date:  2004-02       Impact factor: 2.129

7.  Pharmacokinetics and lung tissue concentrations of tulathromycin in swine.

Authors:  H A Benchaoui; M Nowakowski; J Sherington; T G Rowan; S J Sunderland
Journal:  J Vet Pharmacol Ther       Date:  2004-08       Impact factor: 1.786

Review 8.  Efficacy of the avermectins against filarial parasites: a short review.

Authors:  W C Campbell
Journal:  Vet Res Commun       Date:  1982-05       Impact factor: 2.459

9.  Synthesis and activity of a novel class of tribasic macrocyclic antibiotics: the triamilides.

Authors:  Michael A Letavic; Brian S Bronk; Camilla D Bertsche; Jeffrey M Casavant; Hengmiao Cheng; Kirsten L Daniel; David M George; Shigeru F Hayashi; Barbara J Kamicker; Nicole L Kolosko; Laura J L Norcia; Vanessa D Oberton; Margaret A Rushing; Sheryl L Santoro
Journal:  Bioorg Med Chem Lett       Date:  2002-10-07       Impact factor: 2.823

10.  In vitro microbiological characterization of a novel azalide, two triamilides and an azalide ketal against bovine and porcine respiratory pathogens.

Authors:  Laura J L Norcia; Annette M Silvia; Sheryl L Santoro; Jim Retsema; Michael A Letavic; Brian S Bronk; Kristin M Lundy; Bingwei Yang; Nigel A Evans; Shigeru F Hayashi
Journal:  J Antibiot (Tokyo)       Date:  2004-04       Impact factor: 2.649
View more
  3 in total

1.  Assessment of Draxxin® (tulathromycin) as an inhibitor of in vitro growth of Babesia bovis, Babesia bigemina and Theileria equi.

Authors:  Marta G Silva; Nicolas F Villarino; Donald P Knowles; Carlos E Suarez
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-04-17       Impact factor: 4.077

2.  Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites.

Authors:  Leanne M Low; Aloysious Ssemaganda; Xue Q Liu; Mei-Fong Ho; Victoria Ozberk; James Fink; Lana Sundac; Kylie Alcorn; Amy Morrison; Kevin O'Callaghan; John Gerrard; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2018-12-19       Impact factor: 3.441

3.  Intestinal short-chain fatty acid composition does not explain gut microbiota-mediated effects on malaria severity.

Authors:  Shubham Chakravarty; Rabindra K Mandal; Morgan L Duff; Nathan W Schmidt
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.